48 results on '"Toffoletti, Eleonora"'
Search Results
2. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission
3. The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutations
4. Optimal timing of molecular monitoring after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia
5. BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment‐free remission: A study from the “GRUPPO TRIVENETO LMC”
6. Molecular Tumor Board: A bottom-up approach as method for change.
7. Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia
8. BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment‐free remission: A study from the "GRUPPO TRIVENETO LMC".
9. A Novel ELISA-Based Peptide Biosensor Assay for Screening ABL1 Activity in vitro: A Challenge for Precision Therapy in BCR-ABL1 and BCR-ABL1 Like Leukemias
10. WT1 – Gene expression driven pre-emptive treatment with decitabine for molecular relapse of acute myeloid leukemia after allogeneic stem cell transplant
11. Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia
12. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years
13. BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients
14. BCR-ABL1 Levels at First Month after TKI Discontinuation Predict Subsequent Maintenance of Treatment-Free Remission: A Study from the "Gruppo Triveneto LMC"
15. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia
16. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia
17. brain natriuretic peptide level as marker of cardiac function in imatinib—treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy
18. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation
19. Comparative Monitoring of Minimal Residual Disease (MRD) By RT-Quantitative (RT-qPCR) and Digital PCR (dPCR) in Ph+ Chronic Myeloid Leukemia (CML) Patients Treated with TKIs for Recognition of Stable Deep Molecular Response (DMR) and Identification of Best Candidates to TKIs Treatment Discontinuation
20. Expression and modulation of S100A4 protein by human mast cells
21. Targeting Kinase-activating Genetic Lesions to Improve Therapy of Pediatric Acute Lymphoblastic Leukemia
22. Single Step Multiple Genotyping by MALDI-TOF Mass Spectrometry, for Evaluation of Minor Histocompatibility Antigens in Patients Submitted to Allogeneic Stem Cell Transplantation from HLA-Matched Related and Unrelated Donor
23. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia
24. Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories
25. Optimal timing of molecular monitoring after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia.
26. Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia
27. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduce intensity conditioning allogenic stem cell transplantation in acute myeloid leukaemia
28. ABCG2 but Not ABCB1 RNA Levels at Diagnosis and during Treatment Correlates with Response to Imatinib and 2G-Tkis Front-Line Therapy in Chronic Phase CML Patients
29. Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors
30. Immunogenetic Characterization of Primary Immune Thrombocytopenia (ITP) in Adults: Results of the Unit Study
31. High-Sensitivity Hematopoietic Chimerism By qPCR For Relapse Prediction and Specific Identification Of HLA Loss Leukemic Variants
32. Immunogenetic Characterization of Primary Immune Thrombocytopenia (ITP) in Adults: Preliminary Results of the Unit Study.
33. Clonality and Phenotype in Spleens From Patients with Primary Immune Thrombocytopenia,
34. Q141K Polymorphism of ABCG2 Protein Is Associated with Poor Prognosis In Adult Acute Myeloid Leukemia Treated with a Idarubicin-Based Chemotherapy Protocol
35. Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients
36. Clinical Presentation, Outcome and Risk Factors of Late-Onset Non- Infectious Pulmonary Complications After Allogeneic Stem Cell Transplantation
37. Quantitative assessment ofWT1gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia
38. Gemtuzumab-Ozogamicin in Combination with Fludarabine, Cytarabine, Idarubicin (FLAI-GO) as Induction Therapy in CD33-Positive AML patients Younger Than 65 Years. Report of a Multicentric Trial
39. Brain Natriuretic Peptide (BNP) Level as Marker of Cardiac Function in Imatinib - Treated Chronic Myeloid Leukemia Patients: No Evidence of Cardiotoxicity of Imatinib Therapy.
40. Clonality and Phenotype in Spleens From with Primary Immune Thrombocytopenia
41. Expression and modulation of S100A4 protein by human mast cells
42. Targeting kinase-activating genetic lesions to improve therapy of pediatric acute lymphoblastic leukemia
43. Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories
44. Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia
45. The hidden genomic landscape of acute myeloid leukemia: Subclonal structure revealed by undetected mutations
46. No evidences for B-cell clonality by spectratyping analysis in patients with idiopathic thrombocytopenic purpura undergoing rituximab therapy
47. Clonality and Phenotype in Spleens From Patients with Primary Immune Thrombocytopenia
48. No evidences for B-cell clonality by spectratyping analysis in patients with idiopathic thrombocytopenic purpura undergoing rituximab therapy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.